Table 1 Distribution of cases from different sample types in the cohort.

From: Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results

 

CNB(N)

SE(N)

MS(N)

Total

ISH group 1

25

221

12

258a

ISH group 2

3

25

1

29

ISH group 3

1

2

1

4

ISH group 4

14

35

4

53

ISH group 5

96

1195

54

1345b

  1. N: number of cases; ISH: in situ hybridization; CNB: core needle biopsy; SE: surgical excision; MS: metastatic site.
  2. a60 cases with missing data on the tumor characteristics excluded. b61 cases with missing data on the tumor characteristics excluded.
Back to article page